Q-Vax Q热疫苗失败案例,澳大利亚维多利亚州1994-2013年
对1993-2013年维多利亚州卫生部所有急性Q热通报病例进行回顾性审查,659例中34例曾接种疫苗,10例接种前筛查阳性而未能接种。21例在接种前及接种后15天内存在高风险暴露,可能于自然感染潜伏期内接种;13例在接种后超过15天出现症状,可能为首批适当接种后的Q-Vax疫苗失败系列。
要点
- 659例急性Q热通报病例中34例曾接种Q-Vax疫苗,10例因接种前筛查阳性未接种。
- 21例在接种前及接种后15天内存在高风险暴露,可能于自然感染潜伏期内接种。
- 13例在接种后超过15天出现症状,可能为首批适当接种后的Q-Vax疫苗失败系列。
核心结论
- 13例在接种后超过15天出现症状,可能代表首批适当接种后的Q-Vax疫苗失败系列。
- 21例在接种前及接种后15天内存在高风险暴露,可能于自然感染潜伏期内接种。
研究设计与样本
- 对1993-2013年维多利亚州卫生部所有急性Q热通报病例进行回顾性审查,共659例。
主要发现
- 659例急性Q热通报病例中34例曾接种疫苗。
- 10例接种前筛查阳性,未能接种疫苗。
- 21例在接种前及接种后15天内存在高风险暴露,可能于自然感染潜伏期内接种。
- 13例在接种后超过15天出现症状,可能为首批适当接种后的Q-Vax疫苗失败系列。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Q-Vax®, a whole cell formalin inactivated vaccine, is currently the only licensed Q fever vaccine for humans world-wide. Efficacy is high, although vaccine failures have been described for those vaccinated within the incubation of a naturally acquired infection. In Australia, it is widely used to prevent occupational acquisition of Q fever and is the mainstay for outbreak control. A retrospective review of all notified cases of acute Q fever to the Victorian department of health, 1993-2013, revealed 34 of 659 cases were previously vaccinated and 10 cases were positive on pre-vaccination screening, precluding vaccination. Twenty-one cases described high-risk exposures for C. burnetii prior to and within 15 days post vaccination and are likely to have been vaccinated within the incubation period of a natural infection. Thirteen cases described symptom onset more than 15 days post vaccination and thus may represent the first described series of Q-Vax vaccine failures following appropriate vaccination.
引用
- Bond KA, Franklin LJ, Sutton B, et al. Q-Vax Q fever vaccine failures, Victoria, Australia 1994-2013. Vaccine. 2017. PMID: 29132996. doi:10.1016/j.vaccine.2017.10.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。